These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 24195461)

  • 21. RNA interference therapy for glioblastoma.
    Guo D; Wang B; Han F; Lei T
    Expert Opin Biol Ther; 2010 Jun; 10(6):927-36. PubMed ID: 20415602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. siRNA delivery systems for cancer treatment.
    Oh YK; Park TG
    Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delivery of RNA interference therapeutics using polycation-based nanoparticles.
    Howard KA
    Adv Drug Deliv Rev; 2009 Jul; 61(9):710-20. PubMed ID: 19356738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced Delivery of siRNA to Retinal Ganglion Cells by Intravitreal Lipid Nanoparticles of Positive Charge.
    Huang X; Chau Y
    Mol Pharm; 2021 Jan; 18(1):377-385. PubMed ID: 33295773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo application of RNA interference: from functional genomics to therapeutics.
    Lu PY; Xie F; Woodle MC
    Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RNAi nanomedicines: challenges and opportunities within the immune system.
    Weinstein S; Peer D
    Nanotechnology; 2010 Jun; 21(23):232001. PubMed ID: 20463388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery.
    Alabi CA; Love KT; Sahay G; Yin H; Luly KM; Langer R; Anderson DG
    Proc Natl Acad Sci U S A; 2013 Aug; 110(32):12881-6. PubMed ID: 23882076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Research progress on the development of the strategies for siRNAs delivery in vivo].
    Tang D; Mao A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Aug; 29(4):775-9. PubMed ID: 23016434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo delivery of RNAi with lipid-based nanoparticles.
    Huang L; Liu Y
    Annu Rev Biomed Eng; 2011 Aug; 13():507-30. PubMed ID: 21639780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies.
    Vorhies JS; Nemunaitis J
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):373-82. PubMed ID: 17338656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility.
    Kulkarni JA; Cullis PR; van der Meel R
    Nucleic Acid Ther; 2018 Jun; 28(3):146-157. PubMed ID: 29683383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth.
    Kang MR; Yang G; Place RF; Charisse K; Epstein-Barash H; Manoharan M; Li LC
    Cancer Res; 2012 Oct; 72(19):5069-79. PubMed ID: 22869584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel therapeutic strategy for cartilage diseases based on lipid nanoparticle-RNAi delivery system.
    Wang S; Wei X; Sun X; Chen C; Zhou J; Zhang G; Wu H; Guo B; Wei L
    Int J Nanomedicine; 2018; 13():617-631. PubMed ID: 29440889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells.
    Landesman-Milo D; Goldsmith M; Leviatan Ben-Arye S; Witenberg B; Brown E; Leibovitch S; Azriel S; Tabak S; Morad V; Peer D
    Cancer Lett; 2013 Jul; 334(2):221-7. PubMed ID: 22935680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing the heterogeneity level in lipid nanoparticles for siRNA delivery: size-based separation, compositional heterogeneity, and impact on bioperformance.
    Zhang J; Pei Y; Zhang H; Wang L; Arrington L; Zhang Y; Glass A; Leone AM
    Mol Pharm; 2013 Jan; 10(1):397-405. PubMed ID: 23210488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanoparticle-based delivery system for application of siRNA in vivo.
    Wang Y; Li Z; Han Y; Liang LH; Ji A
    Curr Drug Metab; 2010 Feb; 11(2):182-96. PubMed ID: 20359287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RNAi therapeutics: the teenage years.
    Perkel JM
    Biotechniques; 2012 Jun; 52(6):355-7. PubMed ID: 22668413
    [No Abstract]   [Full Text] [Related]  

  • 40. Nanoparticle-siRNA: A potential cancer therapy?
    Young SW; Stenzel M; Yang JL
    Crit Rev Oncol Hematol; 2016 Feb; 98():159-69. PubMed ID: 26597018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.